BR112012012167A2 - Metabólitos mamíferos de esteróides - Google Patents
Metabólitos mamíferos de esteróidesInfo
- Publication number
- BR112012012167A2 BR112012012167A2 BR112012012167A BR112012012167A BR112012012167A2 BR 112012012167 A2 BR112012012167 A2 BR 112012012167A2 BR 112012012167 A BR112012012167 A BR 112012012167A BR 112012012167 A BR112012012167 A BR 112012012167A BR 112012012167 A2 BR112012012167 A2 BR 112012012167A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- steroid metabolites
- mammalian steroid
- methods
- mammalian
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
COMPOSTO, COMPOSIÇÃO FARMACÊUTICA E USOS DOS MESMOS. São descritos aqui, em certas modalidades, derivados esteroidais, métodos de produção de tais compostos, composições farmacêuticas e medicamentos que compreendem tais compostos, e métodos de utilização de tais compostos para tratar doenças ou condições mediadas por receptor de andrógeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26126209P | 2009-11-13 | 2009-11-13 | |
PCT/US2010/055996 WO2011059969A2 (en) | 2009-11-13 | 2010-11-09 | Mammalian metabolites of steroids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012012167A2 true BR112012012167A2 (pt) | 2017-10-03 |
Family
ID=43992357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012012167A BR112012012167A2 (pt) | 2009-11-13 | 2010-11-09 | Metabólitos mamíferos de esteróides |
Country Status (8)
Country | Link |
---|---|
US (2) | US20120282331A1 (pt) |
EP (1) | EP2499151A4 (pt) |
JP (1) | JP5956928B2 (pt) |
CN (1) | CN102822190B (pt) |
AU (1) | AU2010319697B2 (pt) |
BR (1) | BR112012012167A2 (pt) |
CA (1) | CA2780365A1 (pt) |
WO (1) | WO2011059969A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
AU2010264698C1 (en) | 2009-06-26 | 2013-05-16 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17 |
AU2012249421B9 (en) | 2011-04-28 | 2015-10-22 | Novartis Ag | 17alpha-hydroxylase/C17,20-lyase inhibitors |
EP4066841A1 (en) | 2013-03-14 | 2022-10-05 | University of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
CN105636594A (zh) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
US10675289B2 (en) | 2014-10-02 | 2020-06-09 | University Of Maryland, Baltimore | Methods of treating pancreatic cancer |
WO2016119742A1 (zh) * | 2015-01-29 | 2016-08-04 | 苏州晶云药物科技有限公司 | (3β)-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯-3-醇的盐及其制备方法 |
WO2017140183A1 (zh) * | 2016-02-19 | 2017-08-24 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的甾体类化合物及其应用 |
CN111454315B (zh) * | 2020-04-15 | 2022-12-09 | 宁波第二激素厂 | 一种雄甾-16-烯-3β-醇的合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3480621A (en) * | 1967-01-17 | 1969-11-25 | Phytogen Prod Inc | Steroid ketal |
ES2138618T3 (es) * | 1992-03-31 | 2000-01-16 | Btg Int Ltd | Esteroides 17-sustituidos utiles en el tratamiento del cancer. |
DE4232681C2 (de) * | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
NZ561571A (en) * | 2005-03-02 | 2009-09-25 | Univ Maryland | Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
GB2470873A (en) * | 2008-03-12 | 2010-12-08 | Univ Maryland | Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer |
US20110118219A1 (en) * | 2008-03-25 | 2011-05-19 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
US20110319369A1 (en) * | 2009-02-05 | 2011-12-29 | Tokai Pharmaceuticals, Inc. | Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent |
-
2010
- 2010-11-09 US US13/508,726 patent/US20120282331A1/en not_active Abandoned
- 2010-11-09 CA CA2780365A patent/CA2780365A1/en not_active Abandoned
- 2010-11-09 EP EP10830591A patent/EP2499151A4/en not_active Withdrawn
- 2010-11-09 JP JP2012538889A patent/JP5956928B2/ja not_active Expired - Fee Related
- 2010-11-09 AU AU2010319697A patent/AU2010319697B2/en not_active Ceased
- 2010-11-09 WO PCT/US2010/055996 patent/WO2011059969A2/en active Application Filing
- 2010-11-09 BR BR112012012167A patent/BR112012012167A2/pt not_active IP Right Cessation
- 2010-11-09 CN CN201080059467.3A patent/CN102822190B/zh not_active Expired - Fee Related
-
2016
- 2016-09-22 US US15/273,121 patent/US20170008920A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2780365A1 (en) | 2011-05-19 |
AU2010319697B2 (en) | 2016-05-19 |
WO2011059969A2 (en) | 2011-05-19 |
US20120282331A1 (en) | 2012-11-08 |
WO2011059969A3 (en) | 2011-09-22 |
AU2010319697A1 (en) | 2012-06-07 |
EP2499151A4 (en) | 2013-03-20 |
JP5956928B2 (ja) | 2016-07-27 |
CN102822190B (zh) | 2016-03-30 |
US20170008920A1 (en) | 2017-01-12 |
EP2499151A2 (en) | 2012-09-19 |
JP2013510856A (ja) | 2013-03-28 |
CN102822190A (zh) | 2012-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012012167A2 (pt) | Metabólitos mamíferos de esteróides | |
BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
BR112012020558A2 (pt) | moduladores do receptor de androgênio e seus usos | |
BR112012007102A2 (pt) | compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico | |
BR112015030595A2 (pt) | moduladores de receptor de estrogênio de azetidina e usos dos mesmos | |
BR112013026834A2 (pt) | composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio | |
BR112015022566A2 (pt) | composto e composição farmacêutica | |
BR112019022512A2 (pt) | Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
BR112015005168A2 (pt) | Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos | |
BR112012007747B8 (pt) | compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos | |
BR112015007878A2 (pt) | composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos | |
SV2011003855A (es) | Heteroarilos sustituidos | |
UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
EA201270800A1 (ru) | С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич | |
BR112012016879A2 (pt) | Derivados de fumarato de acido graxo e seus usos | |
UY32919A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos | |
BR112012008823B8 (pt) | compostos que modulam receptor de androgênio, composição farmacêutica compreendendo os ditos compostos e usos dos mesmos para a prevenção ou tratamento de distúrbios dependentes de receptores de androgênio | |
BR112014021531A8 (pt) | composto, composição farmacêutica e usos dos mesmos | |
BRPI0915680A2 (pt) | miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos | |
MX2011009847A (es) | Agentes antihelminticos y su uso. | |
MY177338A (en) | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance | |
CL2011003079A1 (es) | Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes. | |
UA108858C2 (xx) | Похідні ізоксалідину | |
BR112012028648A2 (pt) | uso cosmético de sulfoniloxibenzilaminas substituídas por n e compostos relacionados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |